Cord Blood to Be Used in Breast Cancer Study

Publication
Article
OncologyONCOLOGY Vol 13 No 8
Volume 13
Issue 8

The Cord Blood Registry, in collaboration with the Cord Blood Donor Foundation, is participating in a Breast Cancer Study at Stanford University School of Medicine. The study, funded by the Susan G. Komen Breast Cancer Foundation, will

The Cord Blood Registry, in collaboration with the Cord Blood Donor Foundation, is participating in a Breast Cancer Study at Stanford University School of Medicine. The study, funded by the Susan G. Komen Breast Cancer Foundation, will examine the potential links of the prenatal environment to the risk of breast cancer in women. Prenatal Cord Blood Registry clients who know they are expecting baby girls will be offered the opportunity to donate plasma for the study.

The Cord Blood Registry is the nation’s largest family umbilical cord blood bank. Umbilical cord blood stem cells can be easily collected and banked for future use as a type of “biological insurance.” Over 12,000 families have chosen to bank stem cells with the registry.

Seeds of Breast Cancer Planted Very Early?

“We are excited about this opportunity of taking advantage of the unique resources at Cord Blood Registry and Cord Blood Donor Foundation,” said Atsuko Shibata, MD, PhD, assistant professor of health research and policy at Stanford. “The major goal of this study is to compare estrogen levels in cord blood among female babies of the four racial/ethnic groups whose breast cancer risk varies significantly. The study relates to the hypothesis that the formation of breast cancer could start very early in a woman’s life. This is an important research question, and yet difficult to study.”

Dr. Shibata, who is the principal investigator, of the study will be testing samples from baby girls that are of African-American, Asian, Caucasian, and Hispanic descent.

“We look forward to collaborating with the Susan G. Komen Breast Cancer Foundation, Stanford University School of Medicine, and Cord Blood Registry on such an important study. Cord blood is not only an invaluable resource in the treatment of diseases, but equally important in the area of research,” said Gloria J. Ochoa, president, Cord Blood Donor Foundation.

Recent Videos
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Heather Zinkin, MD, states that reflexology improved pain from chemotherapy-induced neuropathy in patients undergoing radiotherapy for breast cancer.
Study findings reveal that patients with breast cancer reported overall improvement in their experience when receiving reflexology plus radiotherapy.
Patients undergoing radiotherapy for breast cancer were offered 15-minute nurse-led reflexology sessions to increase energy and reduce stress and pain.
Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.
Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.
The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.